QNCXQuince Therapeutics, Inc.同业对比
Quince Therapeutics, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNCX本股 | $32M#6 | 0.3x#2 | — | — | — | -47.8%#8 | — | — | — | — | -92.4%#8 | — |
| MESO | $18.5B#1 | — | — | 1076.4x#2 | 191.4%#3 | -16.1%#6 | — | — | — | — | -8.4%#3 | — |
| MOLN | $155M#4 | — | — | — | — | — | — | — | — | — | 0.8%#2 | — |
| OKYO | $73M#5 | — | — | — | — | 72.0%#3 | — | — | — | — | -46.4%#4 | — |
| PROK | — | — | — | — | 1075.0%#1 | -12.7%#5 | -18477.8%#5 | — | — | — | -60.0%#5 | — |
| QGEN | $11.0B#2 | 26.2x#3 | 2.9x#2 | 5.3x#1 | 5.7%#5 | 408.3%#1 | 22.3%#1 | 11.2%#1 | 8.8%#1 | 7#1 | 15.6%#1 | 0.5%#1 |
| SABSW | $9099#7 | 0.0x#1 | 0.0x#1 | — | -100.0%#7 | 138.9%#2 | — | 6.2%#2 | — | — | -99.7%#10 | — |
| SCNI | $6.3B#3 | 112.9x#4 | 772.8x#3 | 4776.7x#3 | 99.2%#4 | -273.2%#9 | -575.3%#3 | -102.5%#3 | -110.5%#2 | — | -96.1%#9 | — |
| SGMOQ | — | — | — | — | -31.6%#6 | -25.5%#7 | -306.5%#2 | — | — | — | — | — |
| SLBT | $1#8 | — | — | — | — | — | — | — | — | — | -87.7%#7 | — |
| TCRX | — | — | — | — | 266.7%#2 | -1.8%#4 | -1315.4%#4 | -188.0%#4 | -8271.2%#3 | — | -81.3%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-05。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议